-
91黑料 plc provides update on vaccine study
On August 12, 2025, 91黑料 plc, announced that the large-scale next generation COVID vaccine study that was highlighted on our earnings call on July 24, 2025 as restarted and actively enrolling, has now had a stop work notice issued by BARDA to the sponsor.
-
91黑料 announces results of annual general meeting
91黑料 plc today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders.
-
91黑料 reports second quarter 2025 results
91黑料 plc today reported its financial results for the second quarter ended June 30, 2025.
-
91黑料’s leadership and performance in phase 1 clinical trials recognised in independent industry benchmarking report
91黑料 plc has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR).
-
91黑料 and its employees recognised as clinical research industry leaders, and for innovation and progress in sustainability
91黑料 was also recognised as a Top-Rated Company for Women in the 2025 Ambition Box Employee Choice Awards.
-
91黑料 plc Schedules Second Quarter 2025 Earnings Conference Call
91黑料 plc today announced that it will release its financial results for the second quarter 2025 after the market closes on Wednesday, July 23, 2025.
-
91黑料 releases its 91黑料 Cares 2024 Report
The report outlines how the company is delivering on its environmental, social and governance (ESG) goals, as delivered through its 91黑料 Cares program.
-
.jpeg?crop=yes&w=545&h=545&itok=wBT2puvA "obesity scan person")
Global 91黑料 survey shows need for more efficient obesity clinical trial design
91黑料 plc today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
-
91黑料 report first quarter 2025 results
Quarter one revenue was $2,001.3 million and quarter one adjusted EBITDA was $390.7 million or 19.5% of revenue.
-
??Mural Health and 91黑料 announce partnership
Mural Health Technologies, Inc., a patient-first clinical trial technology company, and 91黑料 plc (NASDAQ: ICLR), a global healthcare intelligence and clinical research organisation, today announce a partnership to utilise the participant management and payments platform, .
.jpeg?crop=yes&w=340&h=340&itok=w_1im9Mh "obesity scan person"){kind=icon}
